Farhad Rafii is a Cardiology physician. OpenAlex indexes 12 publications with 409 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
37 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- NovartisProgram year202512 paymentsResearch$287,507openpaymentsdata.cms.gov ↗
- Eli LillyProgram year20252 paymentsResearch$225,936openpaymentsdata.cms.gov ↗
- BayerProgram year202517 paymentsResearch$64,205openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
83.1%Statin17.3%Atorvastatin Calcium76%Rosuvastatin Calcium19%Pravastatin Sodium3%Simvastatin2%Part D≥352 patientsBeta blocker14.2%Metoprolol Succinate28%Metoprolol Tartrate25%Nebivolol Hcl23%Carvedilol16%Propranolol Hcl3%Bisoprolol Fumarate3%Atenolol1%Sotalol1%Part D<11 patients+ 21 more classes in this area
Blood & clotting
11.1%Factor Xa inhibitor7.9%Eliquis70%Xarelto30%Part D≥140 patientsP2Y12 inhibitor1.7%Clopidogrel100%Part D≥51 patients+ 2 more classes in this area
Metabolism & gastrointestinal
3.8%Potassium supplement1.7%Potassium Chloride100%Part D≥45 patientsSGLT2 inhibitor1.1%Jardiance67%Farxiga33%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 26-A-16687-ACC MINIMAL BLOOD PRESSURE EFFECTS OF INTRANASAL ETRIPAMIL IN TRIALS FOR PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
Journal of the American College of Cardiology
2026 - Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE‐303 Open‐Label Study
Journal of Cardiovascular Electrophysiology
2025 - CONSISTENCY AND PREDICTIVENESS OF CONVERSION AMONG MULTIPLE EPISODES OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT) TREATED WITH ETRIPAMIL: OUTCOMES FROM NODE-303
Journal of the American College of Cardiology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Martin Leon, MD
Columbia University Irving Medical Center
Scott Solomon, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”